touchRESPIRATORY coverage of CHEST 2025:
The CHEST 2025 annual meeting (Oct 19-22, Chicago) brought together respiratory, critical-care, and thoracic specialists for interdisciplinary education, professional development and updates on clinical advances.
Read Dr Jean Elwing’s (UC Medical Center, Cincinnati, OH, USA) personal highlights from the conference below.
-
- The Postgraduate Course: Pulmonary Hypertension – From Basics to Bedside and Theory to Therapy was an exceptional opportunity for an immersive, small group learning experience. The faculty led a highly interactive program that combined focused didactics with an emphasis on hemodynamic interpretation, waveform analysis, risk stratification, and imaging review for chronic thromboembolic disease. The integration of sotatercept into contemporary treatment pathways generated important discussion about how to consistently incorporate risk assessment and more aggressive treatment strategies into PAH care. The session reinforced the value of a multidisciplinary approach and provided practical tools that directly translate into improved patient management.
- The session on Race and Ethnicity in PH: Addressing Gaps in Research and Care highlighted critical disparities in PH recognition, referral patterns, and clinical trial participation among underrepresented patient populations. The faculty presented compelling data illustrating how social determinants of health including geography, socioeconomic status, and cumulative stress burden impact outcomes across PH subgroups. The discussion emphasized tangible strategies to improve minority representation in registries and research and to build more equitable models of access to specialized PH care. This session served as an important reminder of the need to deliberately and systematically address inequities within our field.
-
- The session, Transplant ICU and You: Updates for the Intensivist, addressed a frequently under-recognized but increasingly important intersection between transplant medicine and pulmonary disease. As organ transplant volumes continue to rise, the presenters reviewed essential considerations for managing complex peri-operative patients with portopulmonary hypertension, hepatopulmonary syndrome, and cardiopulmonary comorbidities. The faculty underscored the importance of pre- and post-transplant hemodynamic optimization and highlighted ICU challenges across liver, kidney, lung, and heart transplantation. The session reinforced the critical role of collaboration between PH specialists, intensivists, and transplant teams to improve outcomes for this high-risk population.
Further content in pulmonary hypertension.
Editor: Victoria Smith, Senior Content Editor.
Cite: Inside CHEST 2025: Pulmonary hypertension diagnosis, therapy, and transplant updates. touchRESPIRATORY. 24 November 2025.
This content has been developed independently by Touch Medical Media for touchRESPIRATORY. It is not affiliated with the American College of Chest Physicians. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.
Disclosures:Â Jean Elwing discloses receiving grant/research support from: Acceleron/Merck, Gossamer Bio, Inhibikase, Lung LLC, Novartis, NS Pharma, Pharmosa/Liquidia, Pulmovant, United Therapeutics; serving on advisory boards for: Aerovate, Gossamer Bio, Insmed, Janssen/Actelion/Johnson & Johnson, Liquida, Merck, Pulmovant, United Therapeutics; and receiving honoraria/honorarium from: Janssen/Actelion/Johnson & Johnson.
Related content
- Pulmonary Rehabilitation: Improving Access Through Digital Technologies
- Evolution of Hospitalization Trends and Outcomes in Idiopathic Pulmonary Arterial Hypertension
- Findings from a Phase 2b Trial Evaluating RT234, a Drug-Device Combination for Pulmonary Arterial Hypertension
Register now to receive the touchRESPIRATORY newsletter!
Don’t miss out on hearing about our latest peer reviewed articles, expert opinions, conference news, podcasts and more.
